Published in Ophthalmologica on May 20, 2014
Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome. Saudi J Ophthalmol (2016) 0.75
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 3.15
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol (2012) 2.28
WEDGE-SHAPED SUBRETINAL HYPOREFLECTIVITY IN GEOGRAPHIC ATROPHY. Retina (2015) 2.05
Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet (2011) 1.98
Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol (2007) 1.84
Natural course of adult-onset foveomacular vitelliform dystrophy: a spectral-domain optical coherence tomography analysis. Am J Ophthalmol (2011) 1.60
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology (2013) 1.58
Adult-onset foveomacular vitelliform dystrophy: a study by optical coherence tomography. Am J Ophthalmol (2003) 1.56
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol (2014) 1.56
Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit (2008) 1.42
Preferential hyperacuity perimeter in best vitelliform macular dystrophy. Retina (2011) 1.41
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther (2011) 1.37
Choroidal changes associated with reticular pseudodrusen. Invest Ophthalmol Vis Sci (2012) 1.35
Hyperreflective pyramidal structures on optical coherence tomography in geographic atrophy areas. Retina (2014) 1.31
Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol (2010) 1.30
Pathophysiology of disk-related sciatica. I.--Evidence supporting a chemical component. Joint Bone Spine (2005) 1.28
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother (2007) 1.27
A prospective study of reticular macular disease. Ophthalmology (2011) 1.22
2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs (2011) 1.20
Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol (2009) 1.19
ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration. Am J Ophthalmol (2010) 1.19
Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3. Hum Mol Genet (2012) 1.18
Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol (2007) 1.18
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit (2006) 1.17
Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother (2005) 1.17
Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol (2008) 1.16
Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes. Ophthalmology (2012) 1.16
Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2010) 1.15
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol (2008) 1.12
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics (2009) 1.11
Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci (2012) 1.10
Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophthalmic Inflamm Infect (2011) 1.07
Re: Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina (2014) 1.07
Correspondence. Retina (2015) 1.06
Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol (2009) 1.06
Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina (2010) 1.05
Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol (2007) 1.05
Analysis of progression of reticular pseudodrusen by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci (2012) 1.05
VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol (2010) 1.04
High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. Surv Ophthalmol (2009) 1.04
Genotypic influences on severity of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.03
Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration. Retina (2011) 1.03
High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol (2008) 1.03
Antibodies for biodefense. MAbs (2011) 1.02
A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol (2004) 1.02
TYPE 2 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina (2015) 1.01
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol (2007) 1.00
Lessons learned about pneumonic plague diagnosis from two outbreaks, Democratic Republic of the Congo. Emerg Infect Dis (2011) 0.99
PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population. Mol Vis (2007) 0.99
Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol (2011) 0.99
Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) (2011) 0.99
Correlation of visual function impairment and optical coherence tomography findings in patients with adult-onset foveomacular vitelliform macular dystrophy. Am J Ophthalmol (2008) 0.98
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One (2009) 0.98
rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS One (2009) 0.97
Multimodal imaging of dry age-related macular degeneration. Acta Ophthalmol (2012) 0.96
The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res (2011) 0.96
The humanness of macaque antibody sequences. J Mol Biol (2010) 0.96
Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch's membrane rupture. Graefes Arch Clin Exp Ophthalmol (2009) 0.96
Circulating omega-3 Fatty acids and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2014) 0.95
Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration. Invest Ophthalmol Vis Sci (2014) 0.95
INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up. Retina (2016) 0.94
An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit (2010) 0.94
Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol (2009) 0.94
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF SUBRETINAL FIBROSIS IN AGE-RELATED MACULAR DEGENERATION. Retina (2015) 0.93
Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes. Invest Ophthalmol Vis Sci (2008) 0.93
Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene. Mol Vis (2009) 0.93
A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs (2010) 0.93
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012. MAbs (2013) 0.93
Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol (2013) 0.93
Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine (2005) 0.93
Analysis of retinal flecks in fundus flavimaculatus using high-definition spectral-domain optical coherence tomography. Am J Ophthalmol (2010) 0.92
Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One (2012) 0.92
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res (2011) 0.92
Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Res (2015) 0.91
Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci (2011) 0.91
Impact of reticular pseudodrusen on macular function. Retina (2014) 0.91
Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods (2003) 0.90
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN EARLY TYPE 3 NEOVASCULARIZATION. Retina (2015) 0.90
Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem (2009) 0.90
Microperimetric correlations of autofluorescence and optical coherence tomography imaging in dry age-related macular degeneration. Am J Ophthalmol (2012) 0.90
Insights into pathology of cuticular drusen from integrated confocal scanning laser ophthalmoscopy imaging and corresponding spectral domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol (2011) 0.89
Genetic factors associated with age-related macular degeneration. Ophthalmologica (2011) 0.89
Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res (2011) 0.88
Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Biol (2008) 0.87
Steroids and macular edema from retinal vein occlusion. Eur J Ophthalmol (2011) 0.87
Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine (2012) 0.87